Pappas Ventures

Total investments

51

Average round size

27M

Portfolio companies

36

Rounds per year

1.70

Lead investments

4

Follow on index

0.29

Exits

21

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyDrug DiscoveryPharmaceuticalsHealth CareHealth DiagnosticsMedical DeviceMedicalPharmaceuticalTherapeuticsBiopharma

Summary

Pappas Ventures is the famous VC, which was founded in 1994. The main department of described VC is located in the Durham. The venture was found in North America in United States.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Pappas Ventures, startups are often financed by Asset Management Ventures (AMV), Domain Associates, Frazier Healthcare Partners. The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Morningside Group, Kleiner Perkins. In the next rounds fund is usually obtained by Domain Associates, New Enterprise Associates, Kleiner Perkins.

This Pappas Ventures works on 17 percentage points more the average amount of lead investments comparing to the other organizations. The top amount of exits for fund were in 2010. The top activity for fund was in 2010. The fund is constantly included in 2-6 investment rounds annually. The average startup value when the investment from Pappas Ventures is 100-500 millions dollars. The common things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 11 percentage points less often commits exit comparing to other companies.

We also calculated 4 valuable employees in our database.

Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Health Care, Medical. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline TESARO, Afferent Pharmaceuticals, CardioDx The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.

Show more

Investments analytics

Analytics

Total investments
51
Lead investments
4
Exits
21
Rounds per year
1.70
Follow on index
0.29
Investments by industry
  • Biotechnology (43)
  • Health Care (34)
  • Therapeutics (21)
  • Pharmaceutical (20)
  • Medical Device (14)
  • Show 18 more
Investments by region
  • United States (43)
  • Canada (5)
Peak activity year
2007
Number of Unicorns
1
Number of Decacorns
1

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
16
Avg. valuation at time of investment
131M
Group Appearance index
1.00
Avg. company exit year
11
Avg. multiplicator
4.47
Strategy success index
0.70

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
ApplyBoard 16 Sep 2020 Educational Software, Other Services (B2C Non-Financial), Educational and Training Services (B2C), Information Services (B2C), Internet, Software, Enterprise Software, EdTech, PaaS, E-Commerce Platforms Late Stage Venture 55M Canada, Ontario, Waterloo
Liquidia Technologies 13 Jul 2010 Biotechnology, Therapeutics, Biopharma, Nanotechnology Late Stage Venture 5M United States, North Carolina
Spherics 12 May 2005 Health Care, Medical, Therapeutics Late Stage Venture 26M

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.